Searchable abstracts of presentations at key conferences in endocrinology

ea0029oc9.3 | Endocrine Tumours & Translation | ICEECE2012

The central role of estrogen receptor α in IGF2 dependent adrenocortical carcinoma (ACC) cell proliferation suggests the use of selective estrogen receptor modulators (SERMs) for the treatment of ACC

Sirianni R. , Chimento A. , De Luca A. , Cerquetti L. , Carpinelli G. , Fallo F. , Pilon C. , Arnaldi G. , Stigliano A. , Pezzi V.

Adrenocortical Cancer (ACC) is characterized by an increased production of insulin-like growth factor 2 (IGF2) and by estrogen receptor (ER) α up-regulation. Aim of this study was to define IGF2 and estrogen signaling interactions in ACC, in order to give new indications for a better therapy. To this aim we used H295R cells and human ACC tissues which display common features: IGF2 activation of downstream effector pathways and over-expression of estrogen-related genes inc...

ea0081p423 | Pituitary and Neuroendocrinology | ECE2022

The diagnosis of vertebral fractures on routine chest radiography of acromegaly patients: a real-life study

Sardella Chiara , Urbani Claudio , MARCONCINI GIULIA , Cappellani Daniele , Manetti Luca , De Liperi Annalisa , Romei Chiara , Morganti Riccardo , Marcocci Claudio , Bogazzi Fausto

Objectives: The primary objective was to study the prevalence and the risk factors of vertebral fractures (VFs) in acromegaly patients either at diagnosis of acromegaly or during the follow-up. The role of routine chest radiography for detecting VFs in acromegaly was also evaluated.Design and methods: A retrospective cohort study was performed on 60 consecutive acromegaly patients, in a tertiary referral center. The presence of VFs was firstly evaluated ...

ea0041ep583 | Endocrine Disruptors | ECE2016

Thyroid diseases in the ‘Land of Fires’: results of a single center screening in Acerra (Naples)

Simona Auriemma Renata , Cozzolino Mariaconcetta , Belli Arturo , Fierro Gaetano , Messina Gaetana , De Luca Renato , De Simone Teresa , Rivezzi Matteo , Galdiero Mariano , de Angelis Cristina , Pivonello Rosario , Colao Annamaria

Introduction: Environmental toxins, including those deriving from illegal and hazardous disposal of urban and chemical waste, are known to act as endocrine disruptors and to increase the risk of malignancy and cancer mortality. The present study aimed at investigating prevalence and characteristics of thyroid diseases in the area of Acerra, a town in the perimeter of the so called ‘Land of Fires’.Methods: The screening included subjects aged &#...

ea0037gp.08.02 | Reproduction: Male and endocrine disruptors | ECE2015

Deregulation of Sertoli and Leydig cells function in patients with Klinefelter syndrome as evidenced by testis transcriptome analysis

Ferlin Alberto , D'Aurora Marco , Nicola Marta Di , Garolla Andrea , Toni Luca De , Franchi Sara , Palka Giandomenico , Foresta Carlo , Stuppia Liborio , Gatta Valentina

Background: Klinefelter syndrome (KS) is the most common abnormality of sex chromosomes (47,XXY) and represents the first genetic cause of male infertility. Mechanisms leading to KS testis degeneration are still not completely defined but considered to be mainly the result of germ cells loss. In order to unravel the molecular basis of global testis dysfunction in KS patients, we performed a transcriptome analysis on testis biopsies obtained from six azoospermic non-mosaic KS p...

ea0037ep1132 | Endocrine tumours | ECE2015

High-dose treatment with somatostatin analogues in neuroendocrine tumours

Modica Roberta , Ramundo Valeria , Marciello Francesca , Marotta Vincenzo , Pizza Genoveffa , Carratu Anna Chiara , Roseto Chiara de Luca di , Buonomano Pasqualina , Giordano Carla , Trimarchi Francesco , Colao Annamaria , Faggiano Antongiulio

Somatostatin analogs (SSA) effectively control symptoms in neuroendocrine tumours (NET), besides showing antiproliferative activity. In progressive or metastatic NET, increasing SSA dose or shortening the dosing interval are common clinical practice, though empirical. Aim of this study is to evaluate efficacy and safety of high-dose SSA treatment in patients with progressive disease under standard SSA dose. Twenty-one patients (median age 56.8 years) with NET of different orig...

ea0035p534 | Endocrine tumours and neoplasia | ECE2014

Role of metformin on recurrence-free survival in neuroendocrine tumors

Marciello Francesca , Modica Roberta , Marotta Vincenzo , Ramundo Valeria , Prete Michela Del , Buonomano Pasqualina , Carratu Anna Chiara , de Luca di Roseto Chiara , Picillo Ester , Colao Annamaria , Faggiano Antongiulio

Introduction: Recent data suggest that metformin has antineoplastic properties in different type of cancer. Effects of metformin have never been investigated in neuroendocrine tumors (NET).We aim to determine the role of metformine on recurrence-free survival (RFS) in NET patients.Materials and methods: A retrospective analysis was conducted comparing NET patients with recent diagnosis (<3 year) of diabetes mellitus (with HbA1c...

ea0032p115 | Calcium and Vitamin D metabolism | ECE2013

Cinacalcet in patients with primary hyperparathyroidism (PHPT): comparison between sporadic and MEN1 PHPT

Prete Michela Del , Marotta Vincenzo , Ramundo Valeria , Marciello Francesca , Carratu Anna Chiara , di Roseto Chiara De Luca , Esposito Raffaella , Di Sarno Antonella , Colao Annamaria , Faggiano Antongiulio

Introduction: PHPT is a common endocrine disease characterized by hypercalcemia and different degree of osteoporosis and nephrolithiasis. PHPT arises in the context of an inherited disease in 5% of cases. Multiple endocrine neoplasia type 1 (MEN1) is the commonest cause of inherited PHPT. The main therapeutic approach for PHPT is surgery, however many patients refuse or have contraindications for surgery while others, in particular those with MEN1 PHPT, have persistent/relapsi...

ea0032p520 | Endocrine tumours and neoplasia | ECE2013

Assessment of fatal events in patients with radio-active iodine (RAI)-refractory differentiated thyroid cancer responsive to treatment with sorafenib

Marotta Vincenzo , Del Prete Michela , Ramundo Valeria , Marciello Francesca , Di Sarno Antonella , Esposito Raffaella , Carratu Annachiara , de Luca di Roseto Chiara , Camera Luigi , Colao Annamaria , Faggiano Antongiulio

Introduction: Targeted therapy with the multi-kinase inhibitor sorafenib is effective for treatment of differentiated thyroid cancer (DTC) unresponsive to RAI. Although kinase-inhibitors (KIs) are usually well tolerated, severe and even fatal adverse events are reported. Aim of the study was to assess incidence and characteristics of fatal events in patients with RAI-refractory DTC responsive to treatment with sorafenib.Design: A retrospective analysis o...

ea0032p529 | Endocrine tumours and neoplasia | ECE2013

Familial malignant paraganglioma is long-term stabilized with the tyrosine-kinase inhibitor sunitinib

Ramundo Valeria , Marciello Francesca , Del Prete Michela , Marotta Vincenzo , Esposito Raffaella , Chiara Carratu Anna , de Luca di Roseto Chiara , Colao Annamaria , Faggiano Antongiulio

Introduction: Paragangliomas are neuroectodermal tumors that arise from adrenal medulla or extra-adrenal ganglia and are characterized by high vascularisation. A high rate of these tumours is genetically inherited. For malignant paragangliomas, chemo- and radio-therapy are potentially effective, but tumor response is of short duration and patient prognosis is quite poor. Sunitinib is a tyrosine-kinase inhibitor, targeting VEGFR1, -2, PDGFRα, -β, RET and c-Kit. Recent...

ea0032p541 | Endocrine tumours and neoplasia | ECE2013

Sequential use of the kinase-inhibitors sorafenib and sunitinib in a patient affected with pluri-metastatic iodine-refractory follicular thyroid carcinoma

Marotta Vincenzo , Ramundo Valeria , Marciello Francesca , Del Prete Michela , Di Sarno Antonella , Esposito Raffaella , Carratu Annachiara , de Luca di Roseto Chiara , Camera Luigi , Colao Annamaria , Faggiano Antongiulio

Introduction: Kinase-inhibitors (KIs) are effective for treatment of most aggressive endocrine cancers. The crucial point about treatment with KIs is that these agents are not curative and their effects are at best transitory and are always followed by a restoration of tumour growth and progression. Several retrospective and phase II studies demonstrated efficacy of both sorafenib and sunitib for treatment of iodine refractory differentiated thyroid cancer although results fro...